Literature DB >> 373072

Comparison of glucagon, atropine, and placebo as premedication for endoscopy of the upper gastrointestinal tract.

T Qvigstad, S Larsen, J Myren.   

Abstract

The effects of 0.5 mg glucagon and 0.5 mg atropine given intravenously as premedication in upper gastrointestinal endoscopy have been examined and compared to those of placebo (0.9% NaCl) in a double-blind study involving 36 patients and 1 endoscopist. The results showed no difference between atropine, glucagon, and placebo with regard to vomiting, opening of the pylorus, feeling of discomfort, or the success of the examination. Glucagon significantly reduced peristalsis compared with both atropine (p less than 0.01) and placebo (p less than 0.01). The reflux was also significantly reduced by glucagon compared with both atropine (p less than 0.01) and placebo (p less than 0.01). No difference was found between glucagon and atropine with regard to secretion, but both drugs reduced the secretion compared with placebo (p less than 0.05). Glucagon also reduced the secretion of mucus compared with placebo (p = 0.05). No adverse effects occurred.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 373072     DOI: 10.3109/00365527909179875

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  2 in total

1.  Effect of antispasmodic drugs on endoscopic ultrasound/endoscopic ultrasound-guided fine-needle aspiration: A multicenter randomized controlled trial.

Authors:  Masaki Kuwatani; Hiroshi Kawakami; Tsuyoshi Hayashi; Kazunori Eto; Hiroaki Yamato; Manabu Onodera; Hirohito Naruse; Koji Oba
Journal:  Endosc Ultrasound       Date:  2014-07       Impact factor: 5.628

2.  Effectiveness of oral phloroglucinol as a premedication for unsedated esophagogastroduodenoscopy: A prospective, double-blinded, placebo-controlled, randomized trial.

Authors:  HyeIn Jung; Hyun Jung Kim; Eun Sung Choi; Ju Yup Lee; Kyung Sik Park; Kwang Bum Cho; Yoo Jin Lee
Journal:  PLoS One       Date:  2021-08-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.